Danny Haddad, MD
Nephrology · Jersey City, NJNPI 1235351297
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,120 of the $14,419 with a category attached, or 77.1%. AstraZeneca accounts for 74.8% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $5,813 and has fallen 94.6% since, to $313 in 2025. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $129.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$11K
- Amgen$2K
- Nxstage Medical, Inc.$205
- Otsuka America Pharmaceutical, Inc.$166
- Mallinckrodt Enterprises LLC$157
- Bayer$140
- plus $658 from 14 others
Across 13 payments — averaging $130,881 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Vertex$52K
- AstraZeneca$8K
What the payments were for
- Consulting fees$5003%
- Speaking & faculty fees$11,12077%
- Travel & lodging$400%
- Food & beverage$2,47617%
- Education$2822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 39 | $10,786 |
| Amgen(2 entities) | 14 | $2,307 |
| Nxstage Medical, Inc. | 4 | $205 |
| Otsuka America Pharmaceutical, Inc. | 8 | $166 |
| Mallinckrodt Enterprises LLC | 8 | $157 |
| Bayer | 2 | $140 |
| Amarin Pharma, Inc. | 1 | $117 |
| OPKO Pharmaceuticals, LLC | 7 | $103 |
| GSK | 6 | $90 |
| Travere Therapeutics, Inc. | 5 | $64 |
| Ardelyx, Inc. | 3 | $48 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Fresenius USA Marketing, Inc. | 2 | $38 |
| Vifor Pharma, Inc. | 3 | $36 |
| Calliditas Therapeutics US Inc. | 2 | $34 |
| Akebia Therapeutics Inc | 1 | $22 |
| Novartis | 1 | $18 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,419 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 51 | $176,841 |
| FarxigaDapagliflozin Propanediol | 129 | $138,578 |
| LokelmaSodium Zirconium Cyclosilicate | 78 | $69,496 |
| VeltassaPatiromer Calcium Sorbitex | 57 | $64,992 |
| JardianceEmpagliflozin | 32 | $41,834 |
| KerendiaFinerenone | 29 | $29,999 |
| XphozahTenapanor Hcl | 11 | $29,119 |
| JanuviaSitagliptin Phosphate | 18 | $24,479 |
| Sevelamer Carbonate | 51 | $7,916 |
| DapagliflozinDapagliflozin Propanediol | 12 | $7,060 |
| Cinacalcet Hcl | 18 | $5,201 |
| Valsartan | 121 | $2,361 |
| Hydralazine Hcl | 91 | $1,618 |
| Calcitriol | 80 | $1,526 |
| Amlodipine Besylate | 173 | $1,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $10,786 | $208,074207 claims |
| Fresenius USA Marketing, Inc.Velphoro | $38 | $176,84151 claims |
| Boehringer IngelheimJardiance | $16 | $41,83432 claims |
| BayerKerendia | $140 | $29,99929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Jersey City
- Jayeshkumar PatelJersey City$14K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
- Jeffrey GoodmanFlorham Park$70K
- Arif AsifNeptune$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.